FPI 2068
Alternative Names: [225Ac]-FPI-2068; actinium-225 FPI-2068; AZD-2068; FPI-2068Latest Information Update: 21 Aug 2026
At a glance
- Originator AstraZeneca; Fusion Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Jul 2026 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA due to pharmacokinetics/pharmacodynamics (IV) (AstraZeneca pipeline, July 2026)
- 01 Jul 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Recurrent) in USA (IV) (NCT06147037)
- 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca